Endocrine Abstracts

Background: Type 2 diabetes (T2DM) is associated with increased risk of cardiovascular (CV) complications. Although evidence suggest SGLT–2 inhibitors and GLP–1 receptor agonists to have a protective effect on CV outcomes they are still not available as a second–line therapy in Lithuania because of costs.The aim: To examine the risk of hospitalization for CV events associated with diabetes therapies in patients with T2DM.<p class="a...